Kenneth C. Lasseter

9.0k citations

155 papers · 6.4k indexed · h-index 43

Impact in

Pharmacology top 0.5%
- Inflammatory mediators and NSAID effects
- Pharmacogenetics and Drug Metabolism
Endocrinology, Diabetes and Metabolism top 1%
- Diabetes Treatment and Management

Papers in

Drug Discovery 1
Pharmacology 34
- Pharmacogenetics and Drug Metabolism 23
- Drug-Induced Hepatotoxicity and Protection 11
- Inflammatory mediators and NSAID effects 10

Co-authors: Roger F. Palmer Stacy C. Dilzer John A. Wagner Arturo G. Porras Barry J. Gertz Hui Quan Keith Gottesdiener Gary Herman
Journals: The Journal of Clinical Pharmacology (42 papers)Clinical Pharmacology & Therapeutics (14 papers)Drug Metabolism and Disposition (6 papers)Clinical Pharmacokinetics (5 papers)Antimicrobial Agents and Chemotherapy (4 papers)
Partner nations: United States Switzerland Japan

In The Last Decade

Kenneth C. Lasseter

154 papers receiving 6.0k citations

Peers

Countries citing papers authored by Kenneth C. Lasseter

Since Specialization

Citations

This map shows the geographic impact of Kenneth C. Lasseter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth C. Lasseter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth C. Lasseter more than expected).

Fields of papers citing papers by Kenneth C. Lasseter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth C. Lasseter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth C. Lasseter. The network helps show where Kenneth C. Lasseter may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Kenneth C. Lasseter, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kenneth C. Lasseter Line = papers co-authored together Kenneth C. Lasseter links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	SYNT001: A Humanized IgG4 Monoclonal Antibody That Disrupts the Interaction of FcRn and IgG for the Treatment of IgG-Mediated Autoimmune Diseases Blood ·J. Hu, John Eric Humphries, Kenneth C. Lasseter, Richard S. Blumberg	2017	10
2	Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies Clinical Drug Investigation ·Tracey Roberts, John F. Kokai‐Kun, معصومه آزموده, Mauricio Ávila, Heidi Whalen, J. Andrew Bristol, V. G. Kniazev, James Longstreth, Kenneth C. Lasseter, Joseph Sliman	2016	26
3	An Open-Label Investigation of the Pharmacokinetic Profiles of Lisdexamfetamine Dimesylate and Venlafaxine Extended-Release, Administered Alone and in Combination, in Healthy Adults Clinical Drug Investigation ·James Ermer, W. Graninger, Cynthia Richards, Kenneth C. Lasseter, Sabin Shaji, M Sierpiński, Mary Corcoran, Sandra risa Leiblum, Patrick Martin	2013	15
4	Evaluation of the Single-dose Pharmacokinetics of Bilastine in Subjects with Various Degrees of Renal Insufficiency Clinical Drug Investigation ·Kenneth C. Lasseter, Nils-Tore Mosvold, Anna La Noce, Stacy C. Dilzer	2013	28
5	Asenapine Pharmacokinetics in Hepatic and Renal Impairment Clinical Pharmacokinetics ·Pierre Peeters, Howard N. Bockbrader, Edwin Spaans, Peter Dogterom, Kenneth C. Lasseter, Thomas Marbury, MA Mei-hub, Rik de Greef	2011	21
6	Absence of Pharmacokinetic Interaction Between Intravenous Peramivir and Oral Oseltamivir or Rimantadine in Humans The Journal of Clinical Pharmacology ·George Atiee, Kenneth C. Lasseter, C Anemona, Amy McCullough, Phil Collis, Alan S. Hollister, Jaime E. Hernández	2011	13
7	Influence of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Pharmacokinetics and Pharmacodynamics of Warfarin American Journal of Therapeutics ·Jules I. Schwartz, Fang Liu, Mark Stroh, 久美大里, Amy O. Johnson‐Levonas, Kenneth C. Lasseter, Eseng Lai, John A. Wagner	2009	4
8	The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin European Journal of Clinical Pharmacology ·Yanling He, Ron Sabo, Joelle Campestrini, Dai Arakawa, Monica Ligueros‐Saylan, Kenneth C. Lasseter, Stacy C. Dilzer, David L. Howard, William P. Dole	2007	58
9	Effect of a Single Cyclosporine Dose on the Single‐Dose Pharmacokinetics of Sitagliptin (MK‐0431), a Dipeptidyl Peptidase‐4 Inhibitor, in Healthy Male Subjects The Journal of Clinical Pharmacology ·Rajesh Krishna, Arthur Bergman, Patrick Larson, Josée Côté, Kenneth C. Lasseter, Cheryl Ferrell, Amy Wang, Wei Zeng, Li Chen, John A. Wagner, Gary Herman	2007	56
10	Pharmacokinetic Considerations in Determining the Terminal Elimination Half-Lives of Bisphosphonates Clinical Drug Investigation ·Kenneth C. Lasseter, Arturo G. Porras, Andrew Denker, 松美山﨑, Anastasia G. Daifotis	2005	40
11	Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment European Journal of Clinical Pharmacology ·Steven G. Simonson, Paul Martin, Grant Bickwit, Dennis W. Schneck, Kenneth C. Lasseter, Mike J. Warwick	2003	52
12	Drug interactions between caspofungin and tacrolimus JA Stone, J.E. Chitwood, Peter Wickersham, Paul Deutsch, Gregory A. Winchell, Michael Hesney, Rebecca C. Miller, Amanda Freeman, Stacy C. Dilzer, Kenneth C. Lasseter	2001	17
13	Effect of hepatic insufficiency on the pharmacokinetics of caspofungin Marcele Salles, J.E. Chitwood, Bente Dittmann, Peter Wickersham, Paul Deutsch, Gregory A. Winchell, Michael Hesney, Sheng Bi, J. Wendon, Goutam C. Mistry, Stacy C. Dilzer, Kenneth C. Lasseter	2001	12
14	Interactions between Simvastatin and Troglitazone or Pioglitazone in Healthy Subjects The Journal of Clinical Pharmacology ·Thomayant Prueksaritanont, José María Guerrero Vega, Jamie J. Zhao, Hisham S. Saad-Eldeen, Olga Kuznetsova, Bret J. Musser, Raju D. Amin, Lida Liu, Brad Roadcap, Stacy C. Dilzer, Kenneth C. Lasseter, John Rogers	2001	47
15	Tegaserod does not significantly affect the pharmacokinetics of dextromethorphan in healthy subjects Gastroenterology ·M. Mitsumori, Elizabeth Migoya, Stuart Osborne, Kenneth C. Lasseter, 高沢信司, James F. McLeod	2000	9
16	Pharmacokinetics and Pharmacodynamics of Zolmitriptan in Patients with Mild to Moderate Hypertension: A Double‐Blind, Placebo‐Controlled Study The Journal of Clinical Pharmacology ·Deborah A. Smith, Firas Falih Hamudi, Khadidja Medaoud, Ji-hyun Nam, Stacy C. Dilzer, Kenneth C. Lasseter	1998	15
17	Pharmacodynamics of MK-0963, a new 5α-reductase inhibitor: Effects on serum androgen concentrations Clinical Pharmacology & Therapeutics ·Jules I. Schwartz, Oscar L. Laskin, Ahmad Faris Othman, Patricia M. Patterson, Stephen H. Schneider, Kenneth C. Lasseter, James R. Seibold	1994	1
18	The bioavailability and nonlinear pharmacokinetics of MK‐679 in humans Biopharmaceutics & Drug Disposition ·Haiyung Cheng, Jules I. Schwartz, Charles C. Lin, Raju D. Amin, James R. Seibold, Kenneth C. Lasseter, David L. Ebel, Dominick J. Tocco, John Rogers	1994	2
19	Diurnal blood pressure in patients with mild-to-moderate hypertension treated with once-daily benazepril hydrochloride Clinical Pharmacology & Therapeutics ·Myron H. Weinberger, Henry R. Black, Kenneth C. Lasseter, G. P. Lewis, Catherine MacLeod, Arturo Pascual, Philip G. Zager, Howele M.A.C. Toure, Proschka Gw, David A. Bennett, John J. Whalen	1990	17
20	Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. PubMed ·K. C. Yeh, K.A. Gablin, Jan Blond, Kenneth C. Lasseter, Donald G. Musson, S. Schwartz, Michael E. Smith, S. Solís-Valdéz	1989	135

About Kenneth C. Lasseter

Kenneth C. Lasseter is a scholar working on Drug Discovery, Pharmacology, Transplantation, Endocrinology, Diabetes and Metabolism and Hepatology, having authored 155 papers that have together received 6.4k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (23 papers), Diabetes Treatment and Management (17 papers), Drug Transport and Resistance Mechanisms (16 papers), Drug-Induced Hepatotoxicity and Protection (11 papers), Inflammatory mediators and NSAID effects (10 papers), Hormonal Regulation and Hypertension (9 papers), Blood Pressure and Hypertension Studies (9 papers) and Pharmaceutical studies and practices (7 papers). The work is most often cited by research in Pharmacology (1.4k citations), Endocrinology, Diabetes and Metabolism (1.2k citations), Pharmacology (642 citations), Infectious Diseases (1.1k citations) and Biochemistry (424 citations). Kenneth C. Lasseter has collaborated with scholars based in United States, Switzerland and Japan. Frequent co-authors include Roger F. Palmer, Stacy C. Dilzer, John A. Wagner, Arturo G. Porras, Barry J. Gertz, Hui Quan, Keith Gottesdiener, Gary Herman, Cong Chen and David Sciberras. Their work appears in journals such as The Journal of Clinical Pharmacology, Clinical Pharmacology & Therapeutics, Drug Metabolism and Disposition, Clinical Pharmacokinetics and Antimicrobial Agents and Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact